Colorectal cancer: complexities and challenges in managed care

Area of Science:

• Oncology
• Health Economics
• Managed Care

Background:

• Managed care organizations (MCOs) assess treatment value by balancing advances in care against costs.
• The price of medical treatment is a significant but not sole determinant of value.

Purpose of the Study:

• To review the processes governing treatment decisions for oncologic agents within managed care settings.
• To examine the impact of evolving reimbursement policies on cancer care.

Main Methods:

• Review of treatment decision-making frameworks in managed care.
• Analysis of current and proposed reimbursement strategies for oncology drugs.
• Examination of challenges faced by pharmacy and therapeutics committees.

Main Results:

• Cancer therapies, particularly novel agents, present unique challenges for managed care due to high individual costs and potential population-level impact.
• Shifting Medicare reimbursement from Average Wholesale Price (AWP) to Average Sales Price (ASP) plus 6% creates significant issues for oncologists and practices.
• Expedited drug approval pathways result in limited data for some oncology agents, complicating formulary decisions.

Conclusions:

• Oncology disease management should address patient-centric needs beyond direct cancer treatment, including pain and depression.
• Managed care must adapt evaluation and reimbursement strategies for high-cost, novel cancer therapies.
• Interdisciplinary approaches are crucial for optimizing cancer care within managed care environments.